We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 12, 2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
J. Clin. Oncol 2020 Sep 18;[EPub Ahead of Print], AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, AM Haydon, A Meshcheryakov, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, AM Di Giacomo, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, PC Lorigan, ACJ van Akkooi, C Krepler, N Ibrahim, S Marreaud, M Kicinski, S Suciu, C Robert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading